Fernando Rivera, MD, PhD
A device using tumor treating fields (TTF) that was administered to patients with unresectable pancreatic cancer showed early signs of tolerability and safety when in combination with gemcitabine in the frontline setting, according to results of a study presented at the 2016 ASCO Annual Meeting.1
Additionally, the study continued with a second cohort, to which nab-paclitaxel (Abraxane) was added.
Preliminary data for the glioblastoma patient study may be presented in October 2016 at the ESMO Annual Congress in Copenhagen, Rivera noted.
<<< View more from the 2016 ASCO Annual Meeting
- Rivera F, Gallego J, Guillen C, et al. PANOVA: A pilot study of TTFields concomitant with gemcitabine for front-line therapy of advanced pancreatic adenocarcinoma. J Clin Oncol. 2016;34 (suppl; abstr 4125).
... to read the full story